ADMA Biologics (ADMA) vs PTC Therapeutics (PTCT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
PTC Therapeutics (PTCT) has outperformed ADMA Biologics (ADMA) over the past year, losing 2.0% versus a loss of 29.7%. Over five years, ADMA leads with a +841.8% price change compared with +69.9% for PTCT. PTC Therapeutics is the larger company by market cap ($5.40 billion vs $2.32 billion), about 2.3 times the size.
On valuation, ADMA Biologics trades at a lower forward P/E (11.0x vs 27.3x for PTC Therapeutics). PTC Therapeutics converts more of its revenue into profit, with a net margin of 39.4% versus 28.8%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ADMA | PTCT |
|---|---|---|
| Share price | $10.36 | $64.70 |
| Market cap | $2.32B | $5.40B |
| 1-day change | +0.29% | +3.42% |
| YTD return | -43.20% | -14.82% |
| 1-year return | -29.72% | -1.98% |
| 5-year return | +841.82% | +69.86% |
| P/E ratio (TTM) | 14.80 | — |
| Forward P/E | 10.98 | 27.30 |
| EPS (TTM) | $0.70 | $-0.67 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $510.17M | $1.73B |
| Revenue growth (YoY) | +19.63% | +114.51% |
| Net income (latest FY) | $146.93M | $682.64M |
| Gross margin | 57.39% | — |
| Operating margin | 37.53% | 50.09% |
| Net margin | 28.80% | 39.44% |
| 52-week high | $20.46 | $90.87 |
| 52-week low | $7.21 | $61.23 |
| Distance from 52-week high | -49.36% | -28.80% |
| Analyst consensus | none | buy |
| Avg. price target upside | +64.09% | +56.21% |
| Average volume | 2.66M | 1.14M |
| Shares outstanding | 223.98M | 83.46M |
| Employees | 640 | 991 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PTC Therapeutics is about 2.3 times larger than ADMA Biologics by market value ($5.40B vs $2.32B).
- PTCT has outperformed ADMA by 27.7 percentage points over the past year.
- PTC Therapeutics is more profitable, keeping 39.4 cents of every revenue dollar as net income versus 28.8 cents for ADMA Biologics.
- PTC Therapeutics grew revenue faster in its latest fiscal year (+114.51% vs +19.63%).
About ADMA Biologics
ADMA stock →ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company operates through ADMA BioManufacturing and Plasma Collection Centers segments.
Healthcare · Biotechnology · 640 employees
About PTC Therapeutics
PTCT stock →PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.
Healthcare · Biotechnology · 991 employees
ADMA vs PTCT FAQ
Which is bigger, ADMA Biologics or PTC Therapeutics?
PTC Therapeutics (PTCT) is larger, with a market capitalization of $5.40B compared with $2.32B for ADMA Biologics (ADMA).
Which stock has performed better over the past year, ADMA or PTCT?
PTCT returned -1.98% over the past 12 months, compared with -29.72% for ADMA (price return, excluding dividends). Past performance does not predict future results.
Are ADMA Biologics and PTC Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.